The 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.
- Conference
EACR 2024 Annual Congress: Innovative Cancer Science
Reveal the power of the 6-base genome – introducing duet multiomics solution evoC
10 June 2024
to 13 June 2024
Rotterdam Ahoy, Rotterdam
Visit biomodal at booth
#11
About the event
Find the venue
Presenting at the event
Reveal the power of the 6-base genome
Tom Charlesworth, PhD
Director, Market Strategy and Corporate Development
biomodal
Monday 10 June, 2024 | 13:15-14:00 | Rotterdam Room
Presentation abstract
High-level introduction into how 6-base genome data can be used to build models that accurately predict gene expression, chromatin accessibility, and enhancer status.
Measuring evolutionary trajectories of colorectal cancer in Lynch syndrome using joint genetic and epigenetic profiling
Dr. Maxamilian Mossner
Senior Scientific Officer
The Institute of Cancer Research
Monday 10 June, 2024 | 13:15-14:00 | Rotterdam Room
Presentation abstract
Stay tuned!
Poster Presentation: Refining liquid biopsy with the 6-base genome: Generating more information from cell free DNA
Tom Charlesworth, PhD
Director, Market Strategy and Corporate Development
biomodal
Coming soon!
Presentation abstract
Liquid biopsy for profiling cell free DNA (cfDNA) holds huge promise to transform how we detect and identify cancer, and track residual disease. However, a standard blood draw yields only ~10 ng of cfDNA, of which circulating tumour DNA is a minority. Obtaining maximum information from limited samples is, therefore, crucial. Standard genetic sequencing can only provide actionable mutation information at limited loci. Including epigenetic variation at single-base resolution, by measuring 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), provides the ability to probe more loci and could enable more sensitive liquid biopsy assays from cfDNA.
Poster Presentation - Genetic and Epigenetic study of Formalin-damaged (FFPE) DNA with 6-base
Aurelie Modat
Senior Scientist | NGS | Epigenetics | Liquid Biopsy | Assay and Product Development
biomodal
12 June 2024 between 11:00 – 20:15 in the Poster Area
Presentation abstract
This poster explores the challenges and opportunities associated with extracting high-quality genomic and epigenomic data from formalin-fixed and paraffin-embedded (FFPE) specimens commonly used in research and clinical settings. Using evoC solution, We demonstrate the feasibility of obtaining accurate genetic information as well as distinguishing between 5mC and 5hmC from FFPE cancer samples.
EACR Congress Jun 2024
